- •Preface to the First Edition
- •Preface to the Second Edition
- •Contents
- •Diagnostic Challenges
- •Expert Centers
- •Patient Organizations
- •Clinical Trials
- •Research in Orphan Lung Diseases
- •Orphan Drugs
- •Orphanet
- •Empowerment of Patients
- •Conclusions
- •References
- •Introduction
- •Challenges to Overcome in Order to Undertake Quality Clinical Research
- •Lack of Reliable Data on Prevalence
- •Small Number of Patients
- •Identifying Causation/Disease Pathogenesis
- •Disease Complexity
- •Lack of Access to a Correct Diagnosis
- •Delay in Diagnosis
- •Challenges But Not Negativity
- •Some Success Stories
- •The Means to Overcome the Challenges of Clinical Research: Get Bigger Numbers of Well-Characterized Patients
- •The Importance of Patient Organizations
- •National and International Networks
- •End Points for Trials: Getting Them Right When Numbers Are Small and Change Is Modest
- •Orphan Drug Development
- •Importance of Referral Centers
- •Looking at the Future
- •The Arguments for Progress
- •Concluding Remarks
- •References
- •3: Chronic Bronchiolitis in Adults
- •Introduction
- •Cellular Bronchiolitis
- •Follicular Bronchiolitis
- •Respiratory Bronchiolitis
- •Airway-Centered Interstitial Fibrosis
- •Proliferative Bronchiolitis
- •Diagnosis
- •Chest Imaging Studies
- •Pulmonary Function Testing
- •Lung Biopsy
- •Mineral Dusts
- •Organic Dusts
- •Volatile Flavoring Agents
- •Infectious Causes of Bronchiolitis
- •Idiopathic Forms of Bronchiolitis
- •Connective Tissue Diseases
- •Organ Transplantation
- •Hematopoietic Stem Cell Transplantation
- •Drug-Induced Bronchiolitis
- •Treatment
- •Constrictive Bronchiolitis
- •Follicular Bronchiolitis
- •Airway-Centered Interstitial Fibrosis
- •Proliferative Bronchiolitis
- •References
- •Background and Epidemiology
- •Pathophysiology
- •Host Characteristics
- •Clinical Manifestations
- •Symptoms
- •Laboratory Evaluation
- •Skin Testing
- •Serum Precipitins
- •Eosinophil Count
- •Total Serum Immunoglobulin E Levels
- •Recombinant Antigens
- •Radiographic Imaging
- •Pulmonary Function Testing
- •Histology
- •Diagnostic Criteria
- •Historical Diagnostic Criteria
- •Rosenberg and Patterson Diagnostic Criteria
- •ISHAM Diagnostic Criteria
- •Cystic Fibrosis Foundation Diagnostic Criteria
- •General Diagnostic Recommendations
- •Allergic Aspergillus Sinusitis (AAS)
- •Natural History
- •Treatment
- •Corticosteroids
- •Antifungal Therapy
- •Monoclonal Antibodies
- •Monitoring for Treatment Response
- •Conclusions
- •References
- •5: Orphan Tracheopathies
- •Introduction
- •Anatomical Considerations
- •Clinical Presentation
- •Etiological Considerations
- •Idiopathic Subglottic Stenosis
- •Introduction
- •Clinical Features
- •Pulmonary Function Studies
- •Imaging Studies
- •Bronchoscopy
- •Treatment
- •Introduction and Clinical Presentation
- •Clinical Features
- •Pulmonary Function Studies
- •Imaging Studies
- •Bronchoscopy
- •Treatment
- •Tracheomalacia
- •Introduction
- •Clinical Features
- •Pulmonary Function Studies
- •Imaging Studies
- •Bronchoscopy
- •Treatment
- •Tracheobronchomegaly
- •Introduction
- •Clinical Features
- •Pathophysiology
- •Pulmonary Function Studies
- •Imaging Studies
- •Treatment
- •Tracheopathies Associated with Systemic Diseases
- •Relapsing Polychondritis
- •Introduction
- •Clinical Features
- •Laboratory Findings
- •Pulmonary Function and Imaging Studies
- •Treatment
- •Introduction
- •Clinical Features
- •Pulmonary Function Studies
- •Imaging Studies
- •Bronchoscopy
- •Treatment
- •Tracheobronchial Amyloidosis
- •Introduction
- •Clinical Features
- •Pulmonary Function Studies
- •Imaging Studies
- •Bronchoscopy
- •Treatment
- •Sarcoidosis
- •Introduction
- •Pulmonary Function Studies
- •Imaging Studies
- •Bronchoscopy
- •Treatment
- •Orphan Tracheopathies: Conclusions
- •References
- •6: Amyloidosis and the Lungs and Airways
- •Introduction
- •Diagnosis and Evaluation of Amyloidosis
- •Systemic AA Amyloidosis
- •Systemic AL Amyloidosis
- •Amyloidosis Localised to the Respiratory Tract
- •Laryngeal Amyloidosis
- •Tracheobronchial Amyloidosis
- •Parenchymal Pulmonary Amyloidosis
- •Pulmonary Amyloidosis Associated with Sjögren’s Disease
- •Conclusions
- •References
- •Introduction
- •Pathophysiology
- •Genetic Predisposition
- •Immune Dysregulation
- •Epidemiology
- •Incidence and Prevalence
- •Triggering Factors
- •Clinical Manifestations
- •General Symptoms
- •Pulmonary Manifestations
- •Ear, Nose, and Throat (ENT) Manifestations
- •Neurological Manifestations
- •Skin Manifestations
- •Cardiac Manifestations
- •Gastrointestinal Involvement
- •Renal Manifestations
- •Ophthalmological Manifestations
- •Complementary Investigations
- •Diagnosis
- •Diagnostic Criteria
- •Prognosis and Outcomes
- •Phenotypes According to the ANCA Status
- •Treatment
- •Therapeutic Strategies
- •Remission Induction
- •Maintenance Therapy
- •Other Treatments
- •Prevention of AEs
- •Conclusions
- •References
- •8: Granulomatosis with Polyangiitis
- •A Brief Historical Overview
- •Epidemiology
- •Pathogenesis
- •Clinical Manifestations
- •Constitutional Symptoms
- •Ear, Nose, and Throat (ENT) Manifestations
- •Pulmonary Manifestations
- •Kidney and Urological Manifestations
- •Kidney Manifestations
- •Urological Manifestations
- •Neurological Manifestations
- •Peripheral Nervous System (PNS) Manifestations
- •Central Nervous System (CNS) Manifestations
- •Spinal Cord and Cranial Nerve Involvement
- •Skin and Oral Mucosal Manifestations
- •Eye Manifestations
- •Cardiac Involvement
- •Gastrointestinal Manifestations
- •Gynecological and Obstetric Manifestations
- •Venous Thrombosis and Other Vascular Events
- •Other Manifestations
- •Pediatric GPA
- •Diagnosis
- •Diagnostic Approach
- •Laboratory Investigations
- •Biology
- •Immunology
- •Pathology
- •Treatment
- •Glucocorticoids
- •Cyclophosphamide
- •Rituximab
- •Other Current Induction Approaches
- •Other Treatments in GPA
- •Intravenous Immunoglobulins
- •Plasma Exchange
- •CTLA4-Ig (Abatacept)
- •Cotrimoxazole
- •Other Agents
- •Principles of Treatment for Relapsing and Refractory GPA
- •Outcomes and Prognostic Factors
- •Survival and Causes of Deaths
- •Relapse
- •Damage and Disease Burden on Quality of Life
- •Conclusions
- •References
- •9: Alveolar Hemorrhage
- •Introduction
- •Clinical Presentation
- •Diagnosis (Table 9.1, Fig. 9.3)
- •Pulmonary Capillaritis
- •Histology (Fig. 9.4)
- •Etiologies
- •ANCA-Associated Small Vessel Vasculitis: Granulomatosis with Polyangiitis (GPA)
- •ANCA-Associated Small Vessel Vasculitis: Microscopic Polyangiitis
- •Isolated Pulmonary Capillaritis
- •Systemic Lupus Erythematosus
- •Antiphospholipid Antibody Syndrome
- •Anti-Basement Membrane Antibody Disease (Goodpasture Syndrome)
- •Lung Allograft Rejection
- •Others
- •Bland Pulmonary Hemorrhage (Fig. 9.5)
- •Histology
- •Etiologies
- •Idiopathic Pulmonary Hemosiderosis
- •Drugs and Medications
- •Coagulopathy
- •Valvular Heart Disease and Left Ventricular Dysfunction
- •Other
- •Histology
- •Etiologies
- •Hematopoietic Stem Cell Transplantation (HSCT)
- •Cocaine Inhalation
- •Acute Exacerbation of Interstitial Lung Disease
- •Acute Interstitial Pneumonia
- •Acute Respiratory Distress Syndrome
- •Miscellaneous Causes
- •Etiologies
- •Pulmonary Capillary Hemangiomatosis
- •Treatment
- •Conclusions
- •References
- •Takayasu Arteritis
- •Epidemiology
- •Pathologic Features
- •Pathogenesis
- •Clinical Features
- •Laboratory Findings
- •Imaging Studies
- •Therapeutic Management
- •Prognosis
- •Behçet’s Disease
- •Epidemiology
- •Pathologic Features
- •Pathogenesis
- •Diagnostic Criteria
- •Clinical Features
- •Pulmonary Artery Aneurysm
- •Pulmonary Artery Thrombosis
- •Pulmonary Parenchymal Involvement
- •Laboratory Findings
- •Imaging Studies
- •Therapeutic Management
- •Treatment of PAA
- •Treatment of PAT
- •Prognosis
- •References
- •Introduction
- •Portopulmonary Hypertension (PoPH)
- •Epidemiology and Risk Factors
- •Molecular Pathogenesis
- •PoPH Treatment
- •Hepatopulmonary Syndrome (HPS)
- •Epidemiology and Risk Factors
- •Molecular Pathogenesis
- •HPS Treatment
- •Conclusion
- •References
- •12: Systemic Sclerosis and the Lung
- •Introduction
- •Risk factors for SSc-ILD
- •Genetic Associations
- •Clinical Presentation of SSc-ILD
- •Pulmonary Function Tests (PFTs)
- •Imaging
- •Management
- •References
- •13: Rheumatoid Arthritis and the Lungs
- •Introduction
- •Epidemiology
- •Risk Factors for ILD (Table 13.3)
- •Pathogenesis
- •Clinical Features and Diagnosis
- •Treatments
- •Prognosis
- •Epidemiology
- •Risk Factors
- •Clinical Features, Diagnosis, and Outcome
- •Subtypes or RA-AD
- •Obliterative Bronchiolitis
- •Bronchiectasis
- •COPD
- •Cricoarytenoid Involvement
- •Pleural Disease
- •Conclusion
- •References
- •Introduction
- •Systemic Lupus Erythematosus
- •Epidemiology
- •Pathophysiology
- •Pulmonary Manifestations
- •Pleural Disease
- •Shrinking Lung Syndrome
- •Thrombotic Manifestations
- •Interstitial Lung Disease
- •Other Pulmonary Manifestations
- •Prognosis
- •Sjögren’s Syndrome
- •Epidemiology
- •Pathophysiology
- •Pulmonary Manifestations
- •Airway Disorders
- •Lymphoproliferative Disease
- •Interstitial Lung Disease
- •Prognosis
- •Mixed Connective Tissue Disease
- •Epidemiology
- •Pathophysiology
- •Pulmonary Manifestations
- •Pulmonary Hypertension
- •Interstitial Lung Disease
- •Prognosis
- •Myositis
- •Epidemiology
- •Pathophysiology
- •Pulmonary Manifestations and Treatments
- •Interstitial Lung Disease
- •Respiratory Muscle Weakness
- •Other Pulmonary Manifestations
- •Prognosis
- •Other Therapeutic Options in CTD-ILD
- •Lung Transplantation
- •Conclusion
- •References
- •Introduction
- •Diagnostic Criteria
- •Controversies in the Diagnostic Criteria
- •Typical Clinical Features
- •Disease Progression and Prognosis
- •Summary
- •References
- •Introduction
- •Histiocytes and Dendritic Cells
- •Introduction
- •Cellular and Molecular Pathogenesis
- •Pathology
- •Clinical Presentation
- •Treatment and Prognosis
- •Erdheim-Chester Disease
- •Epidemiology
- •Cellular and Molecular Pathogenesis
- •Histopathology and Immunohistochemistry
- •Clinical Presentation
- •Investigation/Diagnosis
- •Chest Studies
- •Cardiovascular Imaging
- •CNS Imaging
- •Bone Radiography
- •Other Imaging Findings and Considerations
- •Disease Monitoring
- •Pathology
- •Management/Treatment
- •Prognosis
- •Rosai-Dorfman Destombes Disease
- •Epidemiology
- •Etiology/Pathophysiology
- •Histopathology and Immunohistochemistry
- •Clinical Presentation
- •Investigation/Diagnosis
- •Management/Treatment
- •Prognosis
- •Conclusions
- •Diagnostic Criteria for Primary Histiocytic Disorders of the Lung
- •References
- •17: Eosinophilic Pneumonia
- •Introduction
- •Eosinophil Biology
- •Physiologic and Immunologic Role of Eosinophils
- •Release of Mediators
- •Targeting the Eosinophil Cell Lineage
- •Historical Perspective
- •Clinical Presentation
- •Pathology
- •Diagnosis
- •Eosinophilic Lung Disease of Undetermined Cause
- •Idiopathic Chronic Eosinophilic Pneumonia
- •Clinical Features
- •Imaging
- •Laboratory Studies
- •Bronchoalveolar Lavage
- •Lung Function Tests
- •Treatment
- •Outcome and Perspectives
- •Clinical Features
- •Imaging
- •Laboratory Studies
- •Bronchoalveolar Lavage
- •Lung Function Tests
- •Lung Biopsy
- •Treatment and Prognosis
- •Eosinophilic Granulomatosis with Polyangiitis
- •History and Nomenclature
- •Pathology
- •Clinical Features
- •Imaging
- •Laboratory Studies
- •Pathogenesis
- •Diagnosis
- •Treatment and Prognosis
- •Long-Term Outcome
- •Hypereosinophilic Syndrome
- •Pathogenesis
- •Clinical and Imaging Features
- •Laboratory Studies
- •Treatment and Prognosis
- •Eosinophilic Pneumonias of Parasitic Origin
- •Tropical Eosinophilia [191]
- •Ascaris Pneumonia
- •Eosinophilic Pneumonia in Larva Migrans Syndrome
- •Strongyloides Stercoralis Infection
- •Eosinophilic Pneumonias in Other Infections
- •Allergic Bronchopulmonary Aspergillosis
- •Pathogenesis
- •Diagnostic Criteria
- •Biology
- •Imaging
- •Treatment
- •Bronchocentric Granulomatosis
- •Miscellaneous Lung Diseases with Associated Eosinophilia
- •References
- •Introduction
- •Pulmonary Langerhans’ Cell Histiocytosis
- •Epidemiology
- •Pathogenesis
- •Diagnosis
- •Clinical Features
- •Extrathoracic Lesions
- •Pulmonary Function Tests
- •Chest Radiography
- •High-Resolution Computed Tomography (HRCT)
- •Bronchoscopy and Bronchoalveolar Lavage (BAL)
- •Lung Biopsy
- •Pathology
- •Treatment
- •Course and Prognosis
- •Case Report I
- •Introduction
- •Epidemiology
- •Clinical Features
- •Histopathological Findings
- •Radiologic Findings
- •Prognosis and Therapy
- •Desquamative Interstitial Pneumonia
- •Epidemiologic and Clinical Features
- •Histopathological Findings
- •Radiological Findings
- •Prognosis and Therapy
- •Conclusion
- •References
- •19: Lymphangioleiomyomatosis
- •Introduction
- •Pathogenesis
- •Presentation
- •Prognosis
- •Management
- •General Measures
- •Parenchymal Lung Disease
- •Pleural Disease
- •Renal Angiomyolipoma
- •Abdominopelvic Lymphatic Disease
- •Pregnancy
- •Tuberous Sclerosis
- •Drug Treatment
- •Bronchodilators
- •mTOR Inhibitors
- •Anti-Oestrogen Therapy
- •Experimental Therapies
- •Interventions for Advanced Disease
- •Oxygen Therapy
- •Pulmonary Hypertension
- •References
- •20: Diffuse Cystic Lung Disease
- •Introduction
- •Lymphangioleiomyomatosis
- •Pathogenesis
- •Pathologic and Radiographic Characteristics
- •Diagnostic Approach
- •Pulmonary Langerhans Cell Histiocytosis (PLCH)
- •Pathogenesis
- •Pathological and Radiographic Characteristics
- •Diagnostic Approach
- •Birt-Hogg-Dubé Syndrome (BHD)
- •Pathogenesis
- •Pathological and Radiographic Characteristics
- •Diagnostic Approach
- •Lymphoproliferative Disorders
- •Pathogenesis
- •Pathological and Radiographic Characteristics
- •Diagnostic Approach
- •Amyloidosis
- •Light Chain Deposition Disease (LCDD)
- •Conclusion
- •References
- •Introduction
- •Lymphatic Development
- •Clinical Presentation of Lymphatic Disorders
- •Approaches to Diagnosis and Management of Congenital Lymphatic Anomalies
- •Generalized Lymphatic Anomaly
- •Etiopathogenesis
- •Clinical Presentation and Diagnosis
- •Course/Prognosis
- •Management
- •Kaposiform Lymphangiomatosis
- •Etiopathogenesis
- •Clinical Presentation and Diagnosis
- •Management
- •Course/Prognosis
- •Gorham Stout Disease
- •Etiopathogenesis
- •Clinical Presentation and Diagnosis
- •Management
- •Course/Prognosis
- •Channel-Type LM/Central Conducting LM
- •Etiopathogenesis
- •Clinical Presentation and Diagnosis
- •Management
- •Course/Prognosis
- •Yellow Nail Syndrome
- •Etiopathogenesis
- •Clinical Presentation and Diagnosis
- •Management
- •Course/Prognosis
- •Summary
- •References
- •Introduction
- •Historical Note
- •Epidemiology
- •Pathogenesis
- •Surfactant Homeostasis in PAP
- •GM-CSF Signaling Disruption
- •Myeloid Cell Dysfunction
- •GM-CSF Autoantibodies
- •Lymphocytosis
- •Clinical Manifestations
- •Clinical Presentation
- •Secondary Infections
- •Pulmonary Fibrosis
- •Diagnosis
- •Pulmonary Function Testing
- •Radiographic Assessment
- •Bronchoscopy and Bronchoalveolar Lavage
- •Laboratory Studies and Biomarkers
- •GM-CSF Autoantibodies
- •Genetic Testing
- •Lung Pathology
- •Diagnostic Approach to the Patient with PAP
- •Natural History and Prognosis
- •Treatment
- •Whole-Lung Lavage
- •Subcutaneous GM-CSF
- •Inhaled GM-CSF
- •Other Approaches
- •Conclusions and Future Directions
- •References
- •Introduction
- •Epidemiology
- •Gastric Contents
- •Pathobiology of GER/Microaspirate in the Lungs of Patients with IPF
- •GER and the Microbiome
- •Diagnosis
- •Clinical History/Physical Exam
- •Investigations
- •Esophageal Physiology
- •Upper Esophageal Sphincter
- •Esophagus and Peristalsis
- •Lower Esophageal Sphincter and Diaphragm
- •Esophageal pH and Impedance Testing
- •High Resolution Esophageal Manometry
- •Esophagram/Barium Swallow
- •Bronchoalveolar Lavage/Sputum: Biomarkers
- •Treatment
- •Anti-Acid Therapy (PPI/H2 Blocker)
- •GER and Acute Exacerbations of IPF
- •Suggested Approach
- •Summary and Future Directions
- •References
- •Introduction
- •Familial Interstitial Pneumonia
- •Telomere Related Genes
- •Genetic
- •Telomere Length
- •Pulmonary Involvement
- •Interstitial Lung Disease
- •Other Lung Disease
- •Hepatopulmonary Syndrome
- •Emphysema
- •Extrapulmonary Manifestations
- •Mucocutaneous Involvement
- •Hematological Involvement
- •Liver Involvement
- •Other Manifestations
- •Treatment
- •Telomerase Complex Agonists
- •Lung Transplantation
- •Surfactant Pathway
- •Surfactant Protein Genes
- •Pulmonary Involvement
- •Treatment
- •Heritable Forms of Pulmonary Fibrosis with Autoimmune Features
- •TMEM173
- •COPA
- •Pulmonary Alveolar Proteinosis
- •GMCSF Receptor Mutations
- •GATA2
- •MARS
- •Lysinuric Protein Intolerance
- •Lysosomal Diseases
- •Hermansky-Pudlak Syndrome
- •Lysosomal Storage Disorders
- •FAM111B, NDUFAF6, PEPD
- •Conclusion
- •References
- •Introduction
- •Pathophysiology
- •Clinical Presentation
- •Epidemiology
- •Genetic Causes of Bronchiectasis
- •Disorders of Mucociliary Clearance
- •Cystic Fibrosis
- •Primary Ciliary Dyskinesia
- •Other Ciliopathies
- •X-Linked Agammaglobulinemia
- •Chronic Granulomatous Disease and Other Disorders of Neutrophil Function
- •Other Genetic Disorders Predisposing to Bronchiectasis
- •Idiopathic Bronchiectasis
- •Diagnosis of Bronchiectasis
- •Management of Patients with Bronchiectasis
- •Airway Clearance Therapy (ACT)
- •Management of Infections
- •Immune Therapy
- •Surgery
- •Novel Therapies for Managing Cystic Fibrosis
- •Summary
- •References
- •Pulmonary Arteriovenous Malformations
- •Background Pulmonary AVMs
- •Anatomy Pulmonary AVMs
- •Clinical Presentation of Pulmonary AVMs
- •Screening Pulmonary AVMs
- •Treatment Pulmonary AVMs
- •Children with Hereditary Hemorrhagic Telangiectasia
- •Pulmonary Hypertension
- •Pulmonary Hypertension Secondary to Liver Vascular Malformations
- •Pulmonary Arterial Hypertension
- •Background HHT
- •Pathogenesis
- •References
- •27: Pulmonary Alveolar Microlithiasis
- •Introduction
- •Epidemiology
- •Pathogenesis
- •Clinical Features
- •Diagnosis
- •Management
- •Summary
- •References
- •Introduction
- •Hermansky-Pudlak Syndrome
- •Telomerase-Associated Pulmonary Fibrosis
- •Lysosomal Storage Diseases
- •Lysinuric Protein Intolerance
- •Familial Hypocalciuric Hypercalcemia
- •Surfactant Dysfunction Disorders
- •Concluding Remarks
- •References
- •Introduction
- •Background
- •Image Acquisition
- •Key Features of Fibrosis
- •Ancillary Features of Fibrosis
- •Other Imaging Findings in FLD
- •Probable UIP-IPF
- •Indeterminate
- •Alternative Diagnosis
- •UIP in Other Fibrosing Lung Diseases
- •Pleuroparenchymal Fibroelastosis (PPFE)
- •Combined Pulmonary Fibrosis and Emphysema
- •Chronic Hypersensitivity Pneumonitis
- •Other Fibrosing Lung Diseases
- •Fibrosing Sarcoidosis
- •CTD-ILD and Drug-Induced FLD
- •Complications
- •Prognosis
- •Computer Analysis of CT Imaging
- •The Progressive Fibrotic Phenotype
- •Other Imaging Techniques
- •Conclusion
- •References
- •Introduction
- •Bronchoalveolar Lavage (BAL)
- •Technique
- •Interpretation
- •Transbronchial Biopsy (TBB)
- •Transbronchial Lung Cryobiopsy (TLCB)
- •References
- •Introduction
- •Overview of ILD Diagnosis
- •Clinical Assessment
- •Radiological Assessment
- •Laboratory Assessment
- •Integration of Individual Features
- •Multidisciplinary Discussion
- •Diagnostic Ontology
- •Conclusions
- •References
- •Introduction
- •Idiopathic Pulmonary Fibrosis
- •Chronic Hypersensitivity Pneumonitis
- •Connective Tissue Disease
- •Drug-Induced Lung Diseases
- •Radiation Pneumonitis
- •Asbestosis
- •Hermansky-Pudlak Syndrome
- •Risk Factors for Progression
- •Diagnosis
- •Pharmacological Management
- •Conclusions
- •References
- •Historical Perspective
- •Epidemiology and Etiologies
- •Tobacco Smoking and Male Sex
- •Genetic Predisposition
- •Systemic Diseases
- •Other Etiological Contexts
- •Clinical Manifestations
- •Pulmonary Function and Physiology
- •Imaging
- •Computed Tomography Characteristics and Patterns
- •Thick-Walled Large Cysts
- •Imaging Phenotypes
- •Pitfalls
- •Pathology
- •Diagnosis
- •CPFE Is a Syndrome
- •Biology
- •Complications and Outcome
- •Mortality
- •Pulmonary Hypertension
- •Lung Cancer
- •Acute Exacerbation of Pulmonary Fibrosis
- •Other Comorbidities and Complications
- •Management
- •General Measures and Treatment of Emphysema
- •Treatment of Pulmonary Fibrosis
- •Management of Pulmonary Hypertension
- •References
- •Acute Interstitial Pneumonia (AIP)
- •Epidemiology
- •Presentation
- •Diagnostic Evaluation
- •Radiology
- •Histopathology
- •Clinical Course
- •Treatment
- •Epidemiology
- •Presentation
- •Diagnostic Evaluation
- •Radiology
- •Histopathology
- •Clinical Course
- •Desquamative Interstitial Pneumonia (DIP)
- •Presentation
- •Diagnostic Evaluation
- •Radiology
- •Histopathology
- •Clinical Course
- •Treatment
- •Epidemiology
- •Presentation
- •Diagnostic Evaluation
- •Radiology
- •Histopathology
- •Clinical Course
- •Treatment
- •References
- •Organizing Pneumonias
- •Epidemiology
- •Pathogenesis
- •Clinical Features
- •Imaging
- •Multifocal Form
- •Isolated Nodular Form
- •Other Imaging Patterns
- •Histopathological Diagnosis of OP Pattern
- •Etiological Diagnosis of OP
- •Treatment
- •Clinical Course and Outcome
- •Severe Forms of OP with Respiratory Failure
- •Acute Fibrinous and Organizing Pneumonia
- •Granulomatous Organizing Pneumonia
- •Acute Interstitial Pneumonia
- •Epidemiology
- •Clinical Picture
- •Imaging
- •Histopathology
- •Diagnosis
- •Treatment
- •Outcome
- •References
- •36: Pleuroparenchymal Fibroelastosis
- •Introduction
- •Epidemiology
- •Clinical Manifestations
- •Laboratory Findings
- •Respiratory Function
- •Radiologic Features
- •Pathologic Features
- •Diagnosis
- •Treatment
- •Prognosis
- •Conclusions
- •References
- •Introduction
- •Acute Berylliosis
- •Chronic Beryllium Disease
- •Exposure
- •Epidemiology
- •Immunopathogenesis and Pathology
- •Genetics
- •Clinical Description and Natural History
- •Treatment and Monitoring
- •Indium–Tin Oxide-Lung Disease
- •Hard Metal Lung
- •Flock Worker’s Disease
- •Asbestosis
- •Nanoparticle Induced ILD
- •Flavoring-Induced Lung Disease
- •Silica-Induced Interstitial Lung Disease
- •Chronic Silicosis
- •Acute and Accelerated Silicosis
- •Chronic Obstructive Disease in CMDLD
- •Simple CMDLD
- •Complicated CMDLD
- •Conclusion
- •References
- •38: Unclassifiable Interstitial Lung Disease
- •Introduction
- •Diagnostic Scenarios
- •Epidemiology
- •Clinical Presentation
- •Diagnosis
- •Clinical Features
- •Radiology
- •Laboratory Investigations
- •Pathology
- •Conclusion
- •References
- •39: Lymphoproliferative Lung Disorders
- •Introduction
- •Nodular Lymphoid Hyperplasia
- •Lymphocytic Interstitial Pneumonia (LIP)
- •Follicular Bronchitis/Bronchiolitis
- •Castleman Disease
- •Primary Pulmonary Lymphomas
- •Primary Pulmonary MALT B Cell Lymphoma
- •Pulmonary Plasmacytoma
- •Follicular Lymphoma
- •Lymphomatoid Granulomatosis
- •Primary Pulmonary Hodgkin Lymphoma (PPHL)
- •Treatment
- •References
- •Introduction
- •Late-Onset Pulmonary Complications
- •Bronchiolitis Obliterans (BO)
- •Pathophysiology
- •Diagnosis
- •Management of BOS
- •Post-HSCT Organizing Pneumonia
- •Other Late-Onset NonInfectious Pulmonary Complications (LONIPCs)
- •Conclusion
- •References
- •Introduction
- •Pulmonary Hypertension Associated with Sarcoidosis (Group 5.2)
- •PH Associated with Pulmonary Langerhans Cell Histiocytosis (Group 5.2)
- •PH in Combined Pulmonary Fibrosis and Emphysema (Group 3.3)
- •PH Associated with Lymphangioleiomyomatosis (Group 3)
- •Hereditary Hemorrhagic Telangiectasia (Group 1.2)
- •Pulmonary Veno-Occlusive Disease (Group 1.5)
- •Small Patella Syndrome (Group 1.2)
- •Conclusion
- •References
- •Introduction
- •Epidemiology
- •Timing, Chronology, Delay Time
- •Route of Administration
- •Patterns of Involvement [3, 4]
- •Drugs and Agents Fallen Out of Favor
- •Drug-Induced Noncardiac Pulmonary Edema
- •Drug-Induced Cardiogenic Pulmonary Edema
- •The “Chemotherapy Lung”
- •Drug-Induced/Iatrogenic Alveolar Hemorrhage
- •Drugs
- •Superwarfarin Rodenticides
- •Transfusion Reactions: TACO–TRALI
- •Acute Eosinophilic Pneumonia
- •Acute Granulomatous Interstitial Lung Disease
- •Acute Organizing Pneumonia (OP), Bronchiolitis Obliterans Organizing Pneumonia (BOOP), or Acute Fibrinous Organizing Pneumonia (AFOP) Patterns
- •Acute Amiodarone-Induced Pulmonary Toxicity (AIPT)
- •Accelerated Pulmonary Fibrosis
- •Acute Exacerbation of Previously Known (Idiopathic) Pulmonary Fibrosis
- •Anaphylaxis
- •Acute Vasculopathy
- •Drug-Induced/Iatrogenic Airway Emergencies
- •Airway Obstruction as a Manifestation of Anaphylaxis
- •Drug-Induced Angioedema
- •Hematoma Around the Upper Airway
- •The “Pill Aspiration Syndrome”
- •Catastrophic Drug-Induced Bronchospasm
- •Peri-operative Emergencies (Table 42.8)
- •Other Rare Presentations
- •Pulmonary Nodules and Masses
- •Pleuroparenchymal Fibroelastosis
- •Late Radiation-Induced Injury
- •Chest Pain
- •Rebound Phenomenon
- •Recall Pneumonitis
- •Thoracic Bezoars: Gossipybomas
- •Respiratory Diseases Considered Idiopathic That May Be Drug-Induced (Table 42.4)
- •Eye Catchers
- •Conclusion
- •References
- •Cancer Mimics of Organizing Pneumonia
- •Lung Adenocarcinoma/Bronchioloalveolar Carcinoma
- •Primary Pulmonary Lymphoma
- •Cancer Mimics of Interstitial Lung Diseases
- •Lymphangitic Carcinomatosis
- •Epithelioid Hemangio-Endothelioma
- •Lymphomatoid Granulomatosis
- •Cystic Tumors
- •Cavitating Tumors
- •Intrathoracic Pseudotumors
- •Respiratory Papillomatosis
- •Pulmonary Langerhans Cell Histiocytosis
- •References
- •Index
636 |
T. Suda |
|
|
lowing acute exacerbation of PPFE have generally been poor and often fatal. Moreover, precise annual incidence rates or risk factors of acute exacerbation have yet to be fully determined.
Conclusions
PPFE has been recognized as a distinct pattern of pulmonarybrosis with characteristic clinical, radiologic, and histologic features. PPFE has been classi ed as either idiopathic or secondary. iPPFE is currently characterized as a rare IIP, while secondary PPFE is associated with diverse conditions, such as transplantation, dust exposure, autoimmune diseases, and genetic mutations. Given that a variety of conditions cause PPFE, it may represent a pattern of chronic lung injury in response to various stimuli and/or in association with immune dysregulation and genetic predisposition. However, the precise pathogenesis has remained undetermined. While no effective therapy for PPFE has been established, its prognosis remains poor. Recently, awareness for PPFE has considerably increased, leading to studies showing that this disease is not rare as previously considered and that brosis is not con ned to the upper lobes. Practically, validated clinical diagnostic criteria without surgical lung biopsy have been developed considering that performing lung biopsy in patients with PPFE is generally discouraged. Future large- scale studies will be required to further understand the precise clinical behavior and prognosis of PPFE, as well as develop effective treatments.
a |
b |
Clinical Vignette
A 73-year-old man, non-smoker, with no occupational exposure was referred to our hospital due to dry cough, progressive dyspnea on exertion, and weight loss. His physical examination revealed low body mass index (BMI), a fattened thorax, and bilateral ne crackles but no clubbed ngers or skin lesions. Serum KL-6 was slightly increased (563 IU/mL) (normal range: ≤500 IU/mL), while serum SP-D was remarkably elevated (372 ng/mL) (normal range: ≤110 ng/mL). Serological tests revealed no autoantibodies. Pulmonary function test showed low forced vital capacity (FVC) (39.9% predict.), low forced expiratory volume in 1 s (FEV1) (49.8% predict.), normal FEV1/FVC 100%, increased residual volume (RV) (160.5% predict.), and high RV/total lung capacity (TLC) (157.7%). Diffusing capacity for carbon monoxide (DLCO) was decreased (70.4%). Blood gas analysis at room air showed decreased partial pressure of oxygen in arterial blood (PaO2) (68 Torr) and slightly increased partial pressure of carbon monoxide (PaCO2) (51 Torr). Chest radiography and computed tomography exhibited bilateral apical pleural thickening with parenchymal bands and reticulations in the upper lobes (Fig. 36.3a and b). Some reticular opacities were also found in the lower lobes. Based on these ndings, idiopathic pleuroparenchymal broelastosis (iPPFE) was suspected, after which a video-associated thoracoscopic surgical lung
Fig. 36.3 Chest X-ray (a) and coronal section of a chest CT (b) of a patient with idiopathic pleuroparenchymal broelastosis. Upward shift of the bilateral hilar structures on chest x-ray and volume loss of the upper lobes on HRCT scan
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
36 Pleuroparenchymal Fibroelastosis |
637 |
|
|
biopsy was conducted to con rm the diagnosis. The biopsy revealed marked thickening of the visceral pleura and subpleural parenchymal intra-alveolar brosis with massive deposition of elastic bers, which were consistent with the histologic pattern of PPFE. Thus, a diagnosis of iPPFE was established, and the patient had been followed up without treatment. During observation, he had developed intractable pneumothorax three times and eventually died of chronic respiratory failure 3 years after diagnosis.
References
1.\Frankel SK, Cool CD, Lynch DA, Brown KK. Idiopathic pleuroparenchymal broelastosis: description of a novel clinicopathologic entity. Chest. 2004;126(6):2007–13.
2.\Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, et al. An of cial American Thoracic Society/ European Respiratory Society statement: update of the international multidisciplinary classi cation of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188(6):733–48.
3.\Reddy TL, Tominaga M, Hansell DM, von der Thusen J, Rassl D, Parfrey H, et al. Pleuroparenchymal broelastosis: a spectrum of histopathological and imaging phenotypes. Eur Respir J. 2012;40(2):377–85.
4.\Amitani R, Niimi A, Kuse F. Idiopathic pulmonary upper lobebrosis (IPUF). Kokyuu. 1992;11:693–9.
5.\Enomoto Y, Nakamura Y, Satake Y, Sumikawa H, Johkoh T, Colby TV, et al. Clinical diagnosis of idiopathic pleuroparenchymal broelastosis: a retrospective multicenter study. Respir Med. 2017;133:1–5.
6.\Watanabe K, Nagata N, Kitasato Y, Wakamatsu K, Nabeshima K, Harada T, et al. Rapid decrease in forced vital capacity in patients with idiopathic pulmonary upper lobe brosis. Respir Investig. 2012;50(3):88–97.
7.\Ishii H, Watanabe K, Kushima H, Baba T, Watanabe S, Yamada Y, et al. Pleuroparenchymal broelastosis diagnosed by multidisciplinary discussions in Japan. Respir Med. 2018;141:190–7.
8.\Kono M, Fujita Y, Takeda K, Miyashita K, Tsutsumi A, Kobayashi T, et al. Clinical signi cance of lower-lobe interstitial lung disease on high-resolution computed tomography in patients with idiopathic pleuroparenchymal broelastosis. Respir Med. 2019;154:122–6.
9.\Kato M, Sasaki S, Kurokawa K, Nakamura T, Yamada T, Sasano H, et al. Usual interstitial pneumonia pattern in the lower lung lobes as a prognostic factor in idiopathic Pleuroparenchymal broelastosis. Respiration. 2019;97(4):319–28.
10.\von der Thusen JH, Hansell DM, Tominaga M, Veys PA, Ashworth MT, Owens CM, et al. Pleuroparenchymal broelastosis in patients with pulmonary disease secondary to bone marrow transplantation. Mod Pathol. 2011;24(12):1633–9.
11.\Mariani F, Gatti B, Rocca A, Bonifazi F, Cavazza A, Fanti S, et al. Pleuroparenchymal broelastosis: the prevalence of secondary forms in hematopoietic stem cell and lung transplantation recipients. Diagn Interv Radiol. 2016;22(5):400–6.
12.\Ofek E, Sato M, Saito T, Wagnetz U, Roberts HC, Chaparro C, et al. Restrictive allograft syndrome post lung transplantation is characterized by pleuroparenchymal broelastosis. Modern pathology : an of cial journal of the United States and Canadian academy of pathology. Inc. 2013;26(3):350–6.
13.\Beynat-Mouterde C, Beltramo G, Lezmi G, Pernet D, Camus C, Fanton A, et al. Pleuroparenchymal broelastosis as a late complication of chemotherapy agents. Eur Respir J. 2014;44(2):523–7.
14.\Baroke E, Heussel CP, Warth A, Eichinger M, Oltmanns U, Palmowski K, et al. Pleuroparenchymal broelastosis in association with carcinomas. Respirology. 2016;21(1):191–4.
15.\Huang Z, Li S, Zhu Y, Zhu H, Yi X. Pleuroparenchymal broelastosis associated with aluminosilicate dust: a case report. Int J Clin Exp Pathol. 2015;8(7):8676–9.
16.\Xu L, Rassaei N, Caruso C. Pleuroparenchymal broelastosis with long history of Asbestos and silicon exposure. Int J Surg Pathol. 2018;26(2):190–3.
17.\Oda T, Ogura T, Kitamura H, Hagiwara E, Baba T, Enomoto Y, et al. Distinct characteristics of pleuroparenchymal broelastosis with usual interstitial pneumonia compared with idiopathic pulmonary brosis. Chest. 2014;146(5):1248–55.
18.\Enomoto Y, Nakamura Y, Colby TV, Johkoh T, Sumikawa H, Nishimoto K, et al. Radiologic pleuroparenchymal broelastosis- like lesion in connective tissue disease-related interstitial lung disease. PLoS One. 2017;12(6):e0180283.
19.\Jacob J, Odink A, Brun AL, Macaluso C, de Lauretis A, Kokosi M, et al. Functional associations of pleuroparenchymal broelastosis and emphysema with hypersensitivity pneumonitis. Respir Med. 2018;138:95–101.
20.\Cha YJ, Han J, Chung MP, Kim TJ, Shin S. Pleuroparenchymalbroelastosis in heterogeneous clinical conditions: clinicopathologic analysis of 7 cases. Clin Respir J. 2018;12(4):1495–502.
21.\Kushima H, Ishii H, Kinoshita Y, Fujita M, Watanabe K. Chronic pulmonary aspergillosis with Pleuroparenchymal broelastosis- like features. Intern Med. 2019;58(8):1137–40.
22.\Watanabe K. Pleuroparenchymal broelastosis: its clinical characteristics. Curr Respir Med Rev. 2013;9:299–37.
23.\Nakatani T, Arai T, Kitaichi M, Akira M, Tachibana K, Sugimoto C, et al. Pleuroparenchymal broelastosis from a consecutive database: a rare disease entity? Eur Respir J. 2015;45(4):1183–6.
24.\Shioya M, Otsuka M, Yamada G, Umeda Y, Ikeda K, Nishikiori H, et al. Poorer prognosis of idiopathic Pleuroparenchymal broelastosis compared with idiopathic pulmonary brosis in advanced stage. Can Respir J. 2018;2018:6043053.
25.\Fujisawa T, Mori K, Mikamo M, Ohno T, Kataoka K, Sugimoto C, et al. Nationwide cloud-based integrated database of idiopathic interstitial pneumonias for multidisciplinary discussion. Eur Respir J. 2019;53(5):1802243.
26.\Azoulay E, Paugam B, Heymann MF, Kambouchner M, Haloun A, Valeyre D, et al. Familial extensive idiopathic bilateral pleuralbrosis. Eur Respir J. 1999;14(4):971–3.
27.\Nunes H, Jeny F, Bouvry D, Picard C, Bernaudin JF, Menard C, et al. Pleuroparenchymal broelastosis associated with telomerase reverse transcriptase mutations. Eur Respir J. 2017;49(5):1700696.
28.\Newton CA, Batra K, Torrealba J, Meyer K, Raghu G, Garcia CK. Pleuroparenchymal broelastosis associated with telomerase reverse transcriptase mutations. Eur Respir J. 2017;49(5):1700696.
29.\Kusagaya H, Fujisawa T, Enomoto N, Inui N, Nakamura Y, Suda T. Co-occurrence of pneumoperitoneum and pneumothorax in a patient with Pleuroparenchymal broelastosis. Am J Respir Crit Care Med. 2015;191(10):1200–1.
30.\Watanabe S, Waseda Y, Takato H, Matsunuma R, Johkoh T, Egashira R, et al. Pleuroparenchymal broelastosis: distinct pulmonary physiological features in nine patients. Respir Investig. 2015;53(4):149–55.
31.\von der Thusen JH. Pleuroparenchymal broelastosis: its pathological characteristics. Curr Respir Med Rev. 2013;9(4):238–47.
32.\Meignin V, Thivolet-Bejui F, Kambouchner M, Hussenet C, Bondeelle L, Mitchell A, et al. Lung histopathology of non- infectious pulmonary complications after allogeneic haematopoietic stem cell transplantation. Histopathology. 2018;73(5):832–42.
638 |
T. Suda |
|
|
33.\Okimoto T, Tsubata Y, Hamaguchi M, Sutani A, Hamaguchi S, Isobe T. Pleuroparenchymal broelastosis after haematopoietic stem cell transplantation without graft-versus-host disease ndings. Respirol Case Rep. 2018;6(3):e00298.
34.\Hirota T, Fujita M, Matsumoto T, Higuchi T, Shiraishi T, Minami M, et al. Pleuroparenchymal broelastosis as a manifestation of chronic lung rejection? Eur Respir J. 2013;41(1):243–5.
35.\Higo H, Miyahara N, Taniguchi A, Maeda Y, Kiura K. Cause of pleuroparenchymal broelastosis following allogeneic hematopoietic stem cell transplantation. Respir Investig. 2019;57(4):321–4.
36.\Becker CD, Gil J, Padilla ML. Idiopathic pleuroparenchymal broelastosis: an unrecognized or misdiagnosed entity? Mod Pathol. 2008;21(6):784–7.
37.\Piciucchi S, Tomassetti S, Casoni G, Sverzellati N, Carloni A, Dubini A, et al. High resolution CT and histological ndings in idiopathic pleuroparenchymal broelastosis: features and differential diagnosis. Respir Res. 2011;12:111.
38.\Wick MR, Kendall TJ, Ritter JH. Asbestosis: demonstration of distinctive interstitial broelastosis: a pilot study. Ann Diagn Pathol. 2009;13(5):297–302.
39.\Davies D. Ankylosing spondylitis and lung brosis. Q J Med. 1972;41(164):395–417.
40.\Singh R, Sundaram P, Joshi JM. Upper lobe brosis in ulcerative colitis. J Assoc Physicians India. 2003;51:515–7.
41.\Bourke S, Campbell J, Henderson AF, Stevenson RD. Apical pulmonary brosis in psoriasis. Br J Dis Chest. 1988;82(4):444–6.
42.\Harada T, Yoshida Y, Kitasato Y, Tsuruta N, Wakamatsu K, Hirota T, et al. The thoracic cage becomes fattened in the progression of pleuroparenchymal broelastosis. Eur Respir Rev. 2014;23(132):263–6.
43.\Kohno N, Kyoizumi S, Awaya Y, Fukuhara H, Yamakido M, Akiyama M. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. Chest. 1989;96(1):68–73.
44.\Kuroki Y, Takahashi H, Chiba H, Akino T. Surfactant proteins A and D: disease markers. Biochim Biophys Acta. 1998;1408(2–3):334–45.
45.\Takahashi H, Fujishima T, Koba H, Murakami S, Kurokawa K, Shibuya Y, et al. Serum surfactant proteins a and D as prognostic factors in idiopathic pulmonary brosis and their relationship to disease extent. Am J Respir Crit Care Med. 2000;162(3 Pt 1):1109–14.
46.\Sato S, Hanibuchi M, Fukuya A, Yabuki Y, Bando H, Yoshijima T, et al. Idiopathic pleuroparenchymal broelastosis is characterized by an elevated serum level of surfactant protein-D, but not Krebs von den Lungen-6. Lung. 2014;192(5):711–7.
47.\Oyama Y, Enomoto N, Suzuki Y, Kono M, Fujisawa T, Inui N, et al. Evaluation of urinary desmosines as a noninvasive diagnostic biomarker in patients with idiopathic pleuroparenchymal broelastosis (PPFE). Respir Med. 2017;123:63–70.
48.\Bonifazi M, Montero MA, Renzoni EA. Idiopathic Pleuroparenchymal broelastosis. Curr Pulmonol Rep. 2017;6(1):9–15.
49.\Tanizawa K, Handa T, Kubo T, Chen-Yoshikawa TF, Aoyama A, Motoyama H, et al. Clinical signi cance of radiological pleuroparenchymal broelastosis pattern in interstitial lung disease patients registered for lung transplantation: a retrospective cohort study. Respir Res. 2018;19(1):162.
50.\Ishii H, Kinoshita Y, Kushima H, Ogura T, Watanabe K. The upward shift of hilar structures and tracheal deviation in pleuroparenchymal broelastosis. Multidiscip Respir Med. 2019;14:10.
51.\Johkoh T, Fukuoka J, Tanaka T. Rare idiopathic intestinal pneumonias (IIPs) and histologic patterns in new ATS/ERS multidisciplinary classi cation of the IIPs. Eur J Radiol. 2015;84(3):542–6.
52.\Kinoshita Y, Watanabe K, Ishii H, Kushima H, Hamasaki M, Fujita M, et al. Pleuroparenchymal broelastosis as a histological background of autoimmune diseases. Virchows Arch. 2019;474(1):97–104.
53.\Khiroya R, Macaluso C, Montero MA, Wells AU, Chua F, Kokosi M, et al. Pleuroparenchymal broelastosis: a review of histopathologic features and the relationship between histologic parameters and survival. Am J Surg Pathol. 2017;41(12):1683–9.
54.\Rosenbaum JN, Butt YM, Johnson KA, Meyer K, Batra K, Kanne JP, et al. Pleuroparenchymal broelastosis: a pattern of chronic lung injury. Hum Pathol. 2015;46(1):137–46.
55.\Kinoshita Y, Watanabe K, Ishii H, Kushima H, Fujita M, Nabeshima K. Signi cant increases in the density and number of lymphatic vessels in pleuroparenchymal broelastosis. Histopathology. 2018;73(3):417–27.
56.\Enomoto Y, Matsushima S, Meguro S, Kawasaki H, Kosugi I, Fujisawa T, et al. Podoplanin-positive myo broblasts: a pathological hallmark of pleuroparenchymal broelastosis. Histopathology. 2018;72(7):1209–15.
57.\Enomoto N, Kusagaya H, Oyama Y, Kono M, Kaida Y, Kuroishi S, et al. Quantitative analysis of lung elastic bers in idiopathic pleuroparenchymal broelastosis (IPPFE): comparison of clinical, radiological, and pathological ndings with those of idiopathic pulmonary brosis (IPF). BMC Pulm Med. 2014;14:91.
58.\KinoshitaY, Watanabe K, Ishii H, Kushima H, Fujita M, Nabeshima K. Proliferation of elastic bres in idiopathic pulmonary brosis: a whole-slide image analysis and comparison with pleuroparenchymal broelastosis. Histopathology. 2017;71(6):934–42.
59.\Kushima H, Hidaka K, Ishii H, Nakao A, On R, Kinoshita Y, et al. Two cases of pleuroparenchymal broelastosis diagnosed with transbronchial lung biopsy. Respir Med Case Rep. 2016;19:71–3.
60.\Kronborg-White S, Ravaglia C, Dubini A, Piciucchi S, Tomassetti S, Bendstrup E, et al. Cryobiopsies are diagnostic in Pleuroparenchymal and airway-centered broelastosis. Respir Res. 2018;19(1):135.
61.\Watanabe K, Ishii H, Kiyomi F, Terasaki Y, Hebisawa A, Kawabata Y, et al. Criteria for the diagnosis of idiopathic pleuroparenchymalbroelastosis: a proposal. Respir Investig. 2019;57(4):312–20.
62.\Huang H, Feng R, Li S, Wu B, Xu K, Xu Z, et al. A CARE- compliant case report: lung transplantation for a Chinese young man with idiopathic pleuroparenchymal broelastosis. Medicine (Baltimore). 2017;96(19):e6900.
63.\Shimada A, Terada J, Tsushima K, Tateishi Y, Abe R, Oda S, et al. Veno-venous extracorporeal membrane oxygenation bridged living- donor lung transplantation for rapid progressive respiratory failure with pleuroparenchymal broelastosis after allogeneic hematopoietic stem cell transplantation. Respir Investig. 2018;56(3):258–62.
64.\Sato S, Hanibuchi M, Takahashi M, Fukuda Y, Morizumi S, Toyoda Y, et al. A patient with idiopathic Pleuroparenchymal broelastosis showing a sustained pulmonary function due to treatment with pirfenidone. Intern Med. 2016;55(5):497–501.
65.\Nasser M, Chebib N, Philit F, Senechal A, Traclet J, Zarza V, et al. Treatment with nintedanib in patients with pleuroparenchymalbroelastosis. Eur Respir J. 2017;50:PA4876.
66.\Portillo K, Guasch I, Becker C, Andreo F, Fernandez-Figueras MT, Ramirez Ruz J, et al. Pleuroparenchymal broelastosis: a new entity within the Spectrum of rare idiopathic interstitial pneumonias. Case Rep Pulmonol. 2015;2015:810515.
67.\Yanagiya M, Sato M, Kawashima S, Kuwano H, Nagayama K, Nitadori J, et al. Flat chest of Pleuroparenchymal broelastosis reversed by lung transplantation. Ann Thorac Surg. 2016;102(4):e347–9.
68.\Hata A, Nakajima T, Yoshida S, Kinoshita T, Terada J, Tatsumi K, et al. Living donor lung transplantation for Pleuroparenchymalbroelastosis. Ann Thorac Surg. 2016;101(5):1970–2.
69.\Chen F, Matsubara K, Miyagawa-Hayashino A, Tada K, Handa T, Yamada T, et al. Lung transplantation for pleuroparenchymal broelastosis after chemotherapy. Ann Thorac Surg. 2014;98(5):e115–7.
70.\Righi I, Morlacchi L, Rossetti V, Mendogni P, Palleschi A, Tosi D, et al. Lung transplantation as successful treatment of end-stage idio-
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
36 Pleuroparenchymal Fibroelastosis |
639 |
|
|
pathic Pleuroparenchymal broelastosis: a case report. Transplant Proc. 2019;51(1):235–8.
71.\Ali MS, Ramalingam VS, Haasler G, Presberg K. Pleuroparenchymal broelastosis (PPFE) treated with lung transplantation and review of the literature. BMJ Case Rep. 2019;12(4):e229402.
72.\Yoshida Y, Nagata N, Tsuruta N, Kitasato Y, Wakamatsu K, Yoshimi M, et al. Heterogeneous clinical features in patients with pulmonary brosis showing histology of pleuroparenchymal broelastosis. Respir Investig. 2016;54(3):162–9.
73.\Suzuki Y, Yoshimura K, Enomoto Y, Yasui H, Hozumi H, Karayama M, et al. Distinct pro le and prognostic impact of body composition changes in idiopathic pulmonary brosis and idiopathic pleuroparenchymal broelastosis. Sci Rep. 2018;8(1):14074.
74.\Murakami Y, Sakamoto K, Okumura Y, Suzuki A, Mii S, Sato M, Yokoi T, Hashimoto N, Hasegawa Y. Acute Exacerbation of Pleuroparenchymal Fibroelastosis Secondary to Allogenic Hematopoietic Stem Cell Transplantation. Intern Med. 2020;59(21): 2737–43. https://doi.org/10.2169/internalmedicine.4995-20. Epub 2020 Jul 14.